-
Biosyngen to Establish Cell Therapy GMP Facility in Singapore
•
Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at developing the company’s immunotherapy assets to address unmet needs in cancer treatment. The facility will serve as a base for advancing Biosyngen’s pipeline of innovative therapies. Facility Details and Strategic ImportanceThe 1,300-square-meter facility, located in…
-
Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges
•
China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85 billion ($395 million) in revenue during the first half of this year, down 3.4% year-on-year (YOY). Net profits fell 23% YOY to RMB 297 million ($41.1 million). The results reflect ongoing market challenges and policy…
-
Parexel Opens Clinical Study Supply Chain Center in Suzhou
•
US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply chain operation center in Suzhou, Jiangsu Province, China. This new facility will provide critical and ancillary supplies and laboratory logistics services for clinical trials in the Asia Pacific region. Global Network and ServicesThe Suzhou center…
-
Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has been dosed in a Phase I clinical study (ABSK043-101) for its in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor, ABSK043, in patients with advanced solid tumors in China. The drug has previously completed multiple dose…
-
Arctic Vision Enrolls First Patient in Phase III Study for ARVN002
•
China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a Phase III clinical study assessing the efficacy and safety of ARVN002 (atropine sulfate) for arresting myopia progression. The study is being conducted in China and marks a significant step forward in the development of this…
-
3D Medicines Partners with Denfo Medical for Cancer Therapy Development
•
China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group, focusing on the research and development (R&D) and commercialization of novel cancer therapies. The collaboration will also cover cancer chroniclization management and novel drug services. Denfo Medical will leverage its interconnected, digitalized, and intelligent online…
-
Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278
•
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront…
-
Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion
•
Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured an undisclosed amount of funding in a Series D+ financing round. The round was led by existing investor Sherpa Healthcare Partners, with additional contributions from Taiping Fund Management, Triwise Capital, and Far East Horizon, as…
-
Santen Pharmaceutical Launches New Plant Construction in Suzhou
•
Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu Province, China. The 126,000 square meter site is designed to enhance local production capacity for prescription eye drops, anticipating increased demand from the globally aging population. The facility is expected to begin operations in 2025.…
-
Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adults with relapsed or refractory multiple myeloma. The approval is limited to…
-
Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development
•
Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with compatriot Chengdu Ucello Biotechnology Co., Ltd. The collaboration aims to develop universal cell therapies by integrating Eureka’s CellSep series cell preparation system and its world-class EuLV-based lentivirus production system based on stable cell lines into…
-
Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China
•
US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement with China National Pharmaceutical Group Co., Ltd (Sinopharm), granting Sinopharm agency and exclusive importing rights to its oral small molecule COVID-19 drug, molnupiravir, in China. The collaboration will also explore the feasibility of technology transfer…
-
NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation
•
The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for generic quality consistency evaluation (GQCE) work. This batch includes a total of 67 new specifications, among which 15 are injectables. The update aims to further standardize and improve the quality of generic drugs in the…
-
SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results
•
SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private in 2017, has released its 2022 interim report. The company generated RMB 1.475 billion ($204.2 million) in revenues during the first half of this year, up 10.8% year-on-year (YOY). Operating profits grew by 8.4% YOY…
-
Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
•
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in a Phase I clinical study for HBM9378 (SKB378), a next-generation fully human antibody targeting thymic stromal lymphopoietin (TSLP), in patients with moderate-to-severe asthma. The study is being conducted in China and marks a significant step…
-
MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that it has received marketing approval in Colombia for its in-house developed Alwide Plus balloon catheter. This marks another significant milestone in the global expansion of the company’s cardiovascular product portfolio. Product…
-
Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization
•
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based biotech Seagen Inc. (Nasdaq: SGEN) to license development and commercialization rights in Greater China (including mainland China, Hong Kong, Taiwan, and Macau) to Tivdak (tisotumab vedotin). This strategic partnership aims to bring this innovative antibody-drug…
-
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
•
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug (IND) approval from China’s Center for Drug Evaluation (CDE). The company will now commence a pivotal Phase III registration study in China for its TLX250-CDx (89Zr-girentuximab), an imaging agent used to support positron emission tomography…
-
Fosun Pharma Launches 20ml SPSB Liquid Product in US Market
•
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch in the US of its sodium phenylacetate and sodium benzoate (SPSB) liquid product, the only 20ml version available on the market. The product is being launched by its partner MAIA Pharmaceuticals Inc. (MAIA), a specialty…
-
Merck’s Gabor Outlines AI and Biomedicine Strategy in China
•
Allan Gabor, president of Merck KGaA China and executive vice president of Merck Electronics, shared his insights on the Artificial Intelligence (AI) and biomedicine industry in China during the BEYOND Expo. Gabor highlighted Merck’s strategic focus on leveraging AI to enhance drug discovery and development processes. AI in Drug Discovery…
